Core B - Biospecimen/Pathology Core

核心 B - 生物样本/病理学核心

• 批准号: 10434085
• 负责人: Iman Osman
• 金额: $ 25.1万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-19 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10434085
• 关键词: Aliquot; Biological Specimen Banks; Biological Specimen database; Blood; Blood specimen; Caring; Cell Separation; Clinical; Clinical Data; Clinical Trials; Collaborations; Collection; Communities; Cutaneous Melanoma; Data; Databases; Development; Enrollment; Ensure; Feces; Goals; Health; Human; Human Resources; Industry; Informed Consent; Institution; International; Link; Lymphocyte; Metastatic Melanoma; Mission; Molecular; Nucleic Acids; Pathologic; Pathology; Patient Rights; Patients; Peripheral Blood Mononuclear Cell; Phase III Clinical Trials; Plasma; Positioning Attribute; Preparation; Process; Prognostic Marker; Program Research Project Grants; Protocols documentation; Quality Control; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resectable; Resected; Resources; Scientist; Services; Site; Skin Cancer; Structure; T-Lymphocyte; Tissue Sample; Tissues; Translational Research; Unresectable; Whole Blood; Work; biobank; career; clinical development; data anonymization; design; follow-up; industry partner; innovation; melanoma; novel; patient oriented; patient privacy; personalized management; phase III trial; predictive marker; programs; prospective; repository infrastructure; stool sample; tool; translational research program

PROJECT SUMMARY The goal of the NYU Melanoma SPORE Core B (Biospecimen Procurement & Utilization Core) is to stimulate patient-centered melanoma translational research by providing all NYU Melanoma SPORE investigators— including research project co-leaders, Career Enhancement Program (CEP) awardees, and Developmental Research Program (DRP) awardees—with both: 1) access to high-quality melanoma biospecimens linked to prospectively collected clinical and pathological data, and 2) innovative services that promote the aims of those projects. Core B will maintain and expand the clinicopathological data and corresponding biospecimen (tissue, blood, and stool) resources of the NYU Melanoma Clinicopathological-Biospecimen Database and Repository for the SPORE’s study of resected and unresectable metastatic melanoma patients. To execute the central scientific strategy of the NYU Melanoma SPORE, Core B will coordinate with industry partners to ensure the acquisition, processing, and distribution of nearly 10,000 human biospecimens from melanoma patients enrolled in multi-site phase III clinical trials. Core B will process biospecimens, including performing nucleic acid extraction and T-cell isolation, and provide specialized, innovative pathology services to support the aims of full SPORE research projects, CEP projects, and DRP projects. Through a governance committee, Core B will also provide oversight of SPORE biospecimen use. Building on the NYU Melanoma Clinicopathological-Biospecimen Database and Repository’s infrastructure, biospecimen resources, and extensive support of NYU Melanoma Program studies internally and with other institutions, Core B will stimulate collaborations within the NYU Melanoma SPORE community as well as with outside collaborators, including other currently active Melanoma and Skin Cancer SPOREs. Given the considerable translational research infrastructure and resources at NYU, Core B personnel will also work closely with the Administrative Core to ensure the most efficient use of institutional resources without replication of efforts. Overall, Core B will provide high quality, annotated melanoma patient biospecimens to all SPORE studies to support the NYU Melanoma SPORE’s mission to develop clinically impactful prognostic and predictive biomarkers for the personalized management of resectable melanoma patients.

项目总结 纽约大学黑色素瘤孢子核心B(生物质采购与利用核心)的目标是刺激 以患者为中心的黑色素瘤转译研究，提供纽约大学所有黑色素瘤孢子研究人员- 包括研究项目联合负责人、职业提升计划(CEP)获奖者和发展 研究计划(DRP)获奖者-包括：1)获得高质量的黑色素瘤生物样品 前瞻性地收集临床和病理数据，以及2)促进这些目标的创新服务 项目。核心B将维护和扩展临床病理数据和相应的生物标本(组织， 血液和粪便)纽约大学黑色素瘤临床病理-生物医学数据库和资料库 用于对已切除和不可切除的转移性黑色素瘤患者的孢子研究。要执行中央 纽约大学黑色素瘤孢子的科学战略，核心B将与行业合作伙伴协调，以确保 从登记的黑色素瘤患者中获取、处理和分配近10,000个人类生物样本 在多站点III期临床试验中。B核将处理生物标本，包括执行核酸提取 和T细胞分离，并提供专门的、创新的病理服务，以支持完整孢子的目标 研究项目、CEP项目和DRP项目。通过一个治理委员会，核心B还将提供 疏忽孢子生物喷雾剂的使用。建立在纽约大学黑色素瘤临床病理-生物制品基础上 纽约大学黑色素瘤数据库和知识库的基础设施、生物样品资源和广泛的支持 项目内部和与其他机构的研究，核心B将促进纽约大学内部的合作 黑色素瘤孢子社区以及与外部合作者，包括其他目前活跃的黑色素瘤 和皮肤癌孢子。 鉴于纽约大学有大量的翻译研究基础设施和资源，Core B的工作人员也将 与行政核心密切合作，确保最有效地利用机构资源 努力的复制。 总体而言，Core B将向所有孢子研究提供高质量的带注释的黑色素瘤患者生物标本，以 支持纽约大学黑色素瘤孢子的使命，开发临床有效的预后和预测性 可切除黑色素瘤患者个性化治疗的生物标志物。